Serious adverse events assessed using ICH‐GCP · people with cirrhosis who had minimal or overt hepatic encephalopathy or who were at risk for developing hepatic encephalopathy;…
It is very uncertain whether L‐ornithine L‐aspartate changes serious adverse events assessed using ICH‐GCP compared with rifaximin (very low certainty).
1 finding from 1 review
Serious adverse events assessed using ICH‐GCP
It is very uncertain whether L‐ornithine L aspartate changes serious adverse events assessed using ICH‐GCP compared with placebo or no intervention (very low certainty).
1 finding from 1 review
Serious adverse events assessed using ICH‐GCP · people with cirrhosis who had minimal or overt hepatic encephalopathy or who were at risk for developing hepatic encephalopathy;…
It is very uncertain whether L‐ornithine L‐aspartate changes serious adverse events assessed using ICH‐GCP compared with lactulose (very low certainty).
1 finding from 1 review
Adverse effects ‐ Bacterial infection clinical assessment · kidney transplant recipients: steroid‐resistant rejection episodes
It is very uncertain whether antibody changes treatment adverse events: bacterial infection compared with other antibody (stratified by antibody type) (very low certainty).
1 finding from 1 review
Adverse events (number of events) (12 months) · people with acute HBV infection
It is very uncertain whether lamivudine changes adverse events (number of events) (12 months) compared with no intervention (very low certainty).
1 finding from 1 review
Adverse events: General: Severe adverse event · patients with schizophrenia
1 finding from 1 review
Intervention not reported
Severe adverse events: central nervous system · antiretroviral‐naïve individuals
The intervention probably leads to higher severe adverse events: central nervous system (moderate certainty).
1 finding from 1 review
Adverse events associated with transfusion · People with a haematological disorder
1 finding from 1 review
Adverse events Adverse events per participant · people with spasticity following stroke
It is very uncertain whether systemic antispasticity drugs changes adverse events Adverse events per participant compared with placebo (very low certainty).
1 finding from 1 review
Adverse events at post‐treatment not reported · patients with anxiety disorders
1 finding from 1 review
Adverse events at post‐treatment not reported · patients with anxiety disorders
1 finding from 1 review
Adverse events attributed to anti‐D treatment · Rh‐negative women without anti‐D antibodies
1 finding from 1 review
Withdrawals due to adverse events · patients with Crohn's disease (with mixed/low disease activity at baseline)
Infliximab may leads to higher withdrawal due to adverse events (at 52 weeks) compared with biosimilar (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · patients with Crohn's disease (active disease population with clinical response at baseline)
It is very uncertain whether subcutaneous CT‐P13 and purine analogues changes withdrawal due to adverse events (at 30 weeks) compared with intravenous CT‐P13 and purine analogues (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · patients with Crohn's disease (active disease population with clinical response at baseline)
It is very uncertain whether infliximab changes withdrawal due to adverse events (at 56 weeks) compared with adalimumab (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · Participants with Crohn's disease in remission
It is very uncertain whether infliximab combined with purine analogues changes withdrawal due to adverse events (at 48 weeks) compared with purine analogues (very low certainty).
1 finding from 1 review
Adverse events: severe complications at day 21 · bullous pemphigoid
Clobetasol propionate cream may leads to lower adverse events: severe complications at day 21 compared with oral prednisone (low certainty).
1 finding from 1 review
Non‐serious adverse events (range 2–10 months) · adult patients after liver transplantation.
1 finding from 1 review
Adverse events requiring hospitalisation (SAE) · Neonates and caregivers
It is very uncertain whether four per cent chlorhexidine + hand hygiene promotion changes adverse events requiring hospitalisation (SAE) compared with usual care (very low certainty).
1 finding from 1 review
Adverse events: new diagnosis of heart failure · Human trial participants undergoing ablation for atrial fibrillation
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found